Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
Yang J, Weisberg EL, Liu X, Magin RS, Chan WC, Hu B, Schauer NJ, Zhang S, Lamberto I, Doherty L, Meng C, Sattler M, Cabal-Hierro L, Winer E, Stone R, Marto JA, Griffin JD, Buhrlage SJ. Yang J, et al. Among authors: meng c. Leukemia. 2022 Jan;36(1):210-220. doi: 10.1038/s41375-021-01336-9. Epub 2021 Jul 29. Leukemia. 2022. PMID: 34326465
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Weisberg EL, et al. Among authors: meng c. Oncotarget. 2017 Jul 6;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881711 Free PMC article.
Inhibition of USP10 induces degradation of oncogenic FLT3.
Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Weisberg EL, et al. Among authors: meng c. Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2. Nat Chem Biol. 2017. PMID: 28967922 Free PMC article.
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD. Weisberg E, et al. Among authors: meng c. Br J Haematol. 2019 Nov;187(4):488-501. doi: 10.1111/bjh.16092. Epub 2019 Jul 15. Br J Haematol. 2019. PMID: 31309543 Free PMC article.
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Weisberg E, et al. Among authors: meng c. Leukemia. 2020 Feb;34(2):625-629. doi: 10.1038/s41375-019-0552-3. Epub 2019 Aug 27. Leukemia. 2020. PMID: 31455850 Free PMC article. No abstract available.
Inhibition of the deubiquitinase USP10 induces degradation of SYK.
Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, Adamia S, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Yang J, et al. Among authors: meng c. Br J Cancer. 2020 Apr;122(8):1175-1184. doi: 10.1038/s41416-020-0731-z. Epub 2020 Feb 4. Br J Cancer. 2020. PMID: 32015510 Free PMC article.
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Weisberg E, et al. Among authors: meng c. Pharm Res. 2020 Aug 10;37(9):167. doi: 10.1007/s11095-020-02851-7. Pharm Res. 2020. PMID: 32778962 Free PMC article. Review.
2,371 results